These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34667922)

  • 21. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
    Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
    Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B.
    Chhabra A; Spurden D; Fogarty PF; Tortella BJ; Rubinstein E; Harris S; Pleil AM; Mellor J; de Courcy J; Alvir J
    Blood Coagul Fibrinolysis; 2020 Apr; 31(3):186-192. PubMed ID: 32271314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy.
    Chang CY; Lai SW; Cheng MM; Ku JT; Hu SH; Liu YL; Tsai JR; Tsai CH; Cheng CN; Chen YC
    Int J Hematol; 2023 Mar; 117(3):378-387. PubMed ID: 36463568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials.
    Astermark J; Wojciechowski P; Aballéa S; Hakimi Z; Nazir J; Klamroth R
    J Blood Med; 2021; 12():613-621. PubMed ID: 34285621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa.
    Pitance V; Désage S; Lienhart A; Meunier S; Chamouard V
    Haemophilia; 2021 May; 27(3):e368-e375. PubMed ID: 33780111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia.
    Versloot O; Iserman E; Chelle P; Germini F; Edginton AN; Schutgens REG; Iorio A; Fischer K
    Hemasphere; 2022 Apr; 6(4):e694. PubMed ID: 35356797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study.
    Pasi J; Hermans C; Hakimi Z; Nazir J; Aballéa S; Ezzalfani M; Fatoye F
    Ther Adv Hematol; 2022; 13():20406207221079482. PubMed ID: 35237394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.
    Wang M; Álvarez-Román MT; Chowdary P; Quon DV; Schafer K
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):737-744. PubMed ID: 27116081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
    Shapiro A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States.
    Bullement A; Knowles ES; DasMahapatra P; Ali T; Preblick R
    Pharmacoecon Open; 2021 Dec; 5(4):625-633. PubMed ID: 34268704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
    McMullen S; Buckley B; Hall E; Kendter J; Johnston K
    Value Health; 2017 Jan; 20(1):93-99. PubMed ID: 28212975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study.
    Matino D; Iorio A; Keepanasseril A; Germini F; Caillaud A; Carcao M; Hews-Girard J; Iserman E; James P; Lee A; Phua CW; Sun HL; Teitel J; Poon MC
    Res Pract Thromb Haemost; 2022 Mar; 6(3):e12661. PubMed ID: 35386274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
    Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
    Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.